Evaluation of heat-inactivated CCFM1139 and its supernatant for the relief of experimental periodontitis in rats.

Periodontitis is a chronic inflammatory disease induced by subgingival microbial dysbiosis, characterised by inflammation of the soft tissues of the periodontium and progressive loss of alveolar bone. CCFM1139 is a probiotic with the potential to relieve periodontitis and . Due to the cost of active strain in production applications, we considered the effectiveness of bacterial components and metabolites in alleviating experimental periodontitis. Therefore, this study investigated the effect of heat-inactivated CCFM1139 and its supernatant in the development of experimental periodontitis through animal experiments. The results showed that active, heat-inactivated CCFM1139 and its supernatant all significantly reduced IL-1β levels in gingival tissue and serum ( < 0.05). Micro-computed tomography (micro CT) analysis showed that the active and heat-inactivated CCFM1139 reduced alveolar bone loss in rats with periodontitis by 25.6% and 15.9% respectively ( < 0.05), with no change in percentage of bone volume ( > 0.05). In histomorphometric analysis, active CCFM1139 showed better results in reducing alveolar bone loss and reducing inflammatory cell recruitment at the second molar. In addition, there was no significant difference in the number of tartrate-resistant acid phosphatase (TRAP) positive cells after in all experimental groups ( > 0.05). Therefore, heat-inactivated CCFM1139 or its supernatant also have the ability to relieve periodontitis, and their alleviating effect may focus on the regulation of inflammatory response.